Contamination of commercially available quisqualic acid by glutamate-like and aspartate-like substances

Six different batches of the glutamic acid analogue quisqualic acid were analyzed with high-pressure liquid chromatography (HPLC). All batches examined showed contaminant peaks. Different batches had different contaminant peaks and differing amounts of each contaminant. Every batch of quisqualic acid tested demonstrated a contaminant peak which co-eluted with exogenously added glutamic acid. Certain batches possessed a contaminant which co-eluted with aspartic acid. The levels of glutamate-like contamination ranged from 0.08 to 0.60%, and the levels of aspartate-like contamination ranged from undetectable amounts to 0.80%. The amount of combined glutamate- and aspartate-like contamination of each batch of quisqualate correlated very highly with the ability of that batch to interact with non-quisqualate receptors in an autoradiographic binding assay. These non-quisqualate receptors are likely (NMDA) receptors. Thus, when high concentrations of quisqualate are used experimentally, contamination is likely to produce spurious effects at non-quisqualate glutamate receptors. Quisqualate itself may be a more specific agonist than assumed previously.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/28030/1/0000469.pd

Regional distribution and properties of [3H]MK-801 binding sites determined by quantitative autoradiography in rat brain

[3H]MK-801 binding in rat brain was characterized using a quantitative autoradiographic binding assay. [3H]MK-801 binding (5 nM) reached equilibrium by 120 min at 23[deg]C. [3H]MK-801 appeared to label a single high affinity site with an affinity constant of approximately 11 nM. [3H]MK-801 binding was heterogeneously distributed throughout the brain with the following order of binding densities: hippocampal formation > cortical areas > striatum > thalamus.Competitive antagonists, -2-amino-5-phosphonopentanoic acid, -2-amino-7-phosphonoheptanoic acid, 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid, and cis-4-phosphonomethyl-2-piperidine carboxylic acid, inhibited [3H]MK-801 binding. Glycine antagonists, 7-chlorokynurenic acid and kynurenic acid, also inhibited [3H]MK-801 binding. Furthermore, the inhibition of [3H]MK-801 binding by the quinoxalinedione compounds 6-cyano-7-nitroquinoxaline-2,3-dione and 6,7-dinitroquinoxaline-2, 3-dione was reversed by glycine. [3H]MK-801 binding was also inhibited by zinc ions. [3H]MK-801 binding was enhanced by glycine or .These results demonstrate that [3H]MK-801 can be used in a quantitative autoradiographic assay as a functional probe for the receptor complex.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/29627/1/0000716.pd

Cerebellar excitatory amino acid binding sites in normal, granuloprival, and purkinje cell-deficient mice

Using quantitative autoradiography, the cellular localization and characterization of cerebellar excitatory amino acid binding sites in normal, Purkinje cell-deficient and granuloprival (granule cell-deficient) mouse cerebella were investigated. In the molecular layer of normal mouse cerebellum, the quisqualate subtype of excitatory amino acid receptor (assayed by [3H](RS)-[alpha]-amino-3-hydroxy-5-methylisoxazole-4-propionate, quisqualate-sensitive -[3H]glutamate, and [3H]6-cyano-7-nitroquinoxaline-2,3-dione binding) predominated. In the granule cell layer of the cerebellum, -[3H]glutamate and [3H]glycine binding sites were predominant.In the molecular layer of Purkinje cell-deficient mutant mice, [3H](RS)-[alpha]-amino-3-hydroxy-5-methylisoxazole-4-propionate binding sites and [3H]6-cyano-7-nitro-quinoxaline-2,3-dione binding were reduced to 24% (P P 3H]glutamate binding sites were reduced to 54% of control (P 3H]glutamate and [3H]glycine binding were unchanged. In the granule cell layer of these mouse cerebella, there was no change in excitatory amino acid receptor binding.In the molecular layer of granuloprival mouse cerebella, [3H](RS)-[alpha]-amino-3-hydroxy-5-methylisoxa-zole-4-propionate binding was increased to 205% of control (P 3H]6-cyano-7-nitro-quinoxaline-2,3-dione binding was increased to 136% of control (P 3H]glutamate binding was increased to 152% of control (P 3H]glutamate and [3H]glycine binding were unchanged. In areas of granule cell depletion [3H]glutamate and [3H]glycine binding were reduced to 68% (P P These results suggest that three different receptor assays: [3H](RS)-[alpha]-amino-3-hydroxy-5-methylisoxa-zole-4-propionate, quisqualate-sensitive -[3H]glutamate, and [3H]6-cyano-7-nitro-quinoxaline-2,3-dione binding can be used to demonstrate that quisqualate receptor specific binding sites are located on Purkinje cell dendrites in the molecular layer of cerebellum, and that these binding sites apparently up-regulate in response to granule cell ablation and Purkinje cell deafferentation.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/29637/1/0000726.pd

-[3H]Glutamate labels the metabotropic excitatory amino acid receptor in rodent brain

A quantitative autoradiographic assay for a novel -[3H]glutamate binding site in rodent brain has been developed. Binding to this site was distinguished by its high affinity for quisqualate (QA), ibotenate, glutamate and trans-1-amino-cyclopentyl-1,3-dicarboxylic acid (trans-ACPD), but low affinity for [RS]-[alpha]-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), kainate and (NMDA). `AMPA-insensitive, QA-sensitive [3H]glutamate binding' (AiQsGB) had a heterogeneous distribution in rat brain with high levels observed in molecular layer of cerebellum, striatum, and lateral septum. AiQsGB was reduced in molecular layer of cerebellum in mice lacking Purkinje cells. AiQsGB appears to represent binding to the `metabotropic' neuronal excitatory amino acid receptor linked to phosphoinositide metabolism.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/28567/1/0000369.pd

2,4,5-Trihydroxyphenylalanine (6-hydroxy-DOPA) displaces [3H]AMPA binding in rat striatum

Excitatory amino acid (EAA) receptor-mediated events have recently been implicated in dopaminergic mechanisms of neurotoxicity. 2,4,5-Trihydroxyphenylalanine (6-hydroxy-DOPA, TOPA), the ortho-hydroxylated derivative of the dopamine precursor 2,4-dihydroxyphenylalanine (-DOPA), has recently been reported to have neurotoxic properties which are blocked by CNQX, a specific antagonist of the AMPA class of (non-NMDA) EAA receptors. We report here that 6-hydroxy-DOPA is a selective displacer of [3H]AMPA binding in rodent brain. 6-Hydroxy-DOPA was as potent as kainate in displacing [3H]AMPA binding, with an IC50 value of 32 [mu]M. Ineffective displacers of [3H]AMPA binding included dopamine, 6-hydroxydopamine, -DOPA, -DOPA, carbidopa, DOPAC, [beta]-methylamino--alanine, 2,4-dihydroxyphenylacetyl--asparagine, homogentisic acid, 2,4-dihydroxyphenylacetic acid, amantadine, and threo-DOPS. 6-Hydroxy-DOPA (100 [mu]M) also displaced 20% of [3H]kainate binding, but did not displace binding to NMDA, phencyclidine (PCP), or dopaminergic (D1 and D2) receptors. These data raise the possibility that 6-hydroxy-DOPA or another abnormal metabolite of -DOPA could act as an excitotoxic agent via action at AMPA receptors. Given that non-NMDA receptors are postulated to play a role in neurotoxic events, these data provide an additional mechanism via which EAA receptor-mediated events could produce neurodegeneration in areas of brain with dopaminergic innervation.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/29079/1/0000114.pd

Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage

To test the hypotheses that mutant huntingtin protein length and wild-type huntingtin dosage have important effects on disease-related transcriptional dysfunction, we compared the changes in mRNA in seven genetic mouse models of Huntington's disease (HD) and postmortem human HD caudate. Transgenic models expressing short N-terminal fragments of mutant huntingtin (R6/1 and R6/2 mice) exhibited the most rapid effects on gene expression, consistent with previous studies. Although changes in the brains of knock-in and full-length transgenic models of HD took longer to appear, 15- and 22-month CHL2Q150/Q150, 18-month HdhQ92/Q92 and 2-year-old YAC128 animals also exhibited significant HD-like mRNA signatures. Whereas it was expected that the expression of full-length huntingtin transprotein might result in unique gene expression changes compared with those caused by the expression of an N-terminal huntingtin fragment, no discernable differences between full-length and fragment models were detected. In addition, very high correlations between the signatures of mice expressing normal levels of wild-type huntingtin and mice in which the wild-type protein is absent suggest a limited effect of the wild-type protein to change basal gene expression or to influence the qualitative disease-related effect of mutant huntingtin. The combined analysis of mouse and human HD transcriptomes provides important temporal and mechanistic insights into the process by which mutant huntingtin kills striatal neurons. In addition, the discovery that several available lines of HD mice faithfully recapitulate the gene expression signature of the human disorder provides a novel aspect of validation with respect to their use in preclinical therapeutic trial

Efficacies of the new Paclitaxel-eluting Coroflex Please™ Stent in percutaneous coronary intervention; comparison of efficacy between Coroflex Please™ and Taxus™ (ECO-PLEASANT) trial: study rationale and design

<p>Abstract</p> <p>Background</p> <p>Previous randomized trials have showed the superiority of Paclitaxel-eluting stent over bare metal stent in angiographic and clinical outcomes. Coroflex Please™ stent is a newly developed drug eluting stent using the Coroflex™ stent platform combined with the drug paclitaxel contained in a polymer coating. PECOPS I trial, one-arm observational study, showed that the clinical and angiographic outcomes of Coroflex Please™ stent were within the range of those of Taxus, the 1^stgeneration paclitaxel-eluting stent (PES). However, there have been no studies directly comparing the Coroflex Please™ stent with the Taxus Liberte™ stent that is the newest version of Taxus. Therefore, prospective, randomized trial is required to demonstrate the non-inferiority of Coroflex Please™ stent compared with Taxus Liberte™ stent in a head-to-head manner.</p> <p>Methods</p> <p>In the comparison of Efficacy between COroflex PLEASe™ ANd Taxus™ stent(ECO-PLEASANT) trial, approximately 900 patients are being prospectively and randomly assigned to the either type of Coroflex Please™ stent and Taxus Liberte™ stent via web-based randomization. The primary endpoint is clinically driven target vessel revascularization at 9 months. The secondary endpoints include major cardiac adverse events, target vessel failure, stent thrombosis and angiographic efficacy endpoints.</p> <p>Discussion</p> <p>The ECO-PLEASANT trial is the study not yet performed to directly compare the efficacy and safety of the Coroflex Please™ versus Taxus Liberte™ stent. On the basis of this trial, we will be able to find out whether the Coroflex Please™ stent is non-inferior to Taxus Liberte™ stent or not.</p> <p>Trial registration</p> <p>ClinicalTrials.gov number, NCT00699543.</p

Outer Membrane Vesicles as a Candidate Vaccine against Edwardsiellosis

Infection with Edwardsiella tarda, a Gram-negative bacterium, causes high morbidity and mortality in both marine and freshwater fish. Outer membrane vesicles (OMVs) released from Gram-negative bacteria are known to play important roles in bacterial pathogenesis and host immune responses, but no such roles for E. tarda OMVs have yet been described. In the present study, we investigated the proteomic composition of OMVs and the immunostimulatory effect of OMVs in a natural host, as well as the efficacy of OMVs when used as a vaccine against E. tarda infection. A total of 74 proteins, from diverse subcellular fractions, were identified in OMVs. These included a variety of important virulence factors, such as hemolysin, OmpA, porin, GAPDH, EseB, EseC, EseD, EvpC, EvpP, lipoprotein, flagellin, and fimbrial protein. When OMVs were administrated to olive flounder, significant induction of mRNAs encoding IL-1β, IL-6, TNFα, and IFNγ was observed, compared with the levels seen in fish injected with formalin-killed E. tarda. In a vaccine trial, olive flounder given OMVs were more effectively protected (p<0.0001) than were control fish. Investigation of OMVs may be useful not only for understanding the pathogenesis of E. tarda but also in development of an effective vaccine against edwardsiellosis